Granted Patent B2

US 12,208,141 · App. 18/472,993 · Granted Jan 28, 2025

Inventors: David Hung (New York, NY); Son Minh Pham (San Francisco, CA); Sarvajit Chakravarty (Edmond, OK); Jiyun Chen (Moraga, CA); Jayakanth Kankanala (Plymouth, MN); Jeremy D. Pettigrew (Burnaby, CA); Anup Barde (Uttar Pradesh, IN); Anjan Kumar Nayak (Uttar Pradesh, IN)

Assignee: NUVATION BIO INC.

A61K47/55A61K9/0053A61K31/438A61K31/4745A61K31/498A61K31/4985A61K31/502A61K31/5025A61K31/519A61K31/52A61K31/5377A61K31/55A61K47/6877C07D401/12C07D401/14C07D403/12C07D471/04C07D471/06

Abstract

Claims (31)

1. A compound of Formula IID, or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof:

wherein:

L 1 is a covalent bond, optionally substituted alkylene or optionally substituted heteroalkylene; and

R 15 is

2. The compound of claim 1 , or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof, wherein L 1 is a covalent bond or optionally substituted alkylene.

3. The compound of claim 1 , or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof, wherein L 1 is a covalent bond or optionally substituted heteroalkylene.

4. The compound of claim 1 , or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof, wherein L 1 is optionally substituted alkylene or optionally substituted heteroalkylene.

5. The compound of claim 1 , or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof, wherein L 1 is alkylene or heteroalkylene.

6. The compound of claim 1 , or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof, wherein L 1 is a covalent bond.

7. The compound of claim 1 , or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof, wherein L 1 is of the formula:

—Y 1 —(CH 2 ) m —Y 2 —(CH 2 ) p —Y 3 —

wherein each of Y 1 , Y 2 , and Y 3 are independently a bond, —CR 11 R 12 —, —NR 11 —, —O—, —S(O) 0—2 —, —NR 11 C(O)—, —C(O)NR 11 —, —NR 11 S(O) 2 —, —S(O) 2 NR 11 —, or —C(O)—;

each R 11 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl;

each R 12 is independently hydrogen, C1-4 alkyl, C1-4 haloalkyl, aryl, heteroaryl, cycloalkyl or heterocyclyl; and

n and p are each independently 0, 1, 2, 3, 4, 5, 6, 7, or 8.

8. The compound of claim 1 , wherein the compound is selected from the group consisting of:

or a pharmaceutically acceptable salt thereof.

9. A pharmaceutical composition comprising a compound of claim 1 , or a stereoisomer, mixture of stereoisomers, or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

10. A method of treating a blood cancer, lung cancer, breast cancer, fallopian tube cancer, brain cancer, head and neck cancer, esophageal cancer, ovarian cancer, pancreatic cancer, peritoneal cancer, prostate cancer or skin cancer, comprising administering an effective amount of the pharmaceutical composition of claim 9 to an individual in need thereof.

11. A method of treating liver cancer, melanoma, Hodgkin's disease, non-Hodgkin's lymphomas, acute lymphocytic leukemia, chronic lymphocytic leukemia, multiple myeloma, neuroblastoma, breast carcinoma, ovarian carcinoma, lung carcinoma, Wilms' tumor, cervical carcinoma, testicular carcinoma, soft-tissue sarcoma, chronic lymphocytic leukemia, primary macroglobulinemia, bladder carcinoma, chronic granulocytic leukemia, primary brain carcinoma, malignant melanoma, small-cell lung carcinoma, stomach carcinoma, colon carcinoma, malignant pancreatic insulinoma, malignant carcinoid carcinoma, malignant melanoma, choriocarcinoma, mycosis fungoides, head neck carcinoma, osteogenic sarcoma, pancreatic carcinoma, acute granulocytic leukemia, hairy cell leukemia, rhabdomyosarcoma, Kaposi's sarcoma, genitourinary carcinoma, thyroid carcinoma, esophageal carcinoma, malignant hypercalcemia, cervical hyperplasia, renal cell carcinoma, endometrial carcinoma, polycythemia vera, essential thrombocytosis, adrenal cortex carcinoma, skin cancer, or prostatic carcinoma, comprising administering an effective amount of the pharmaceutical composition of claim 9 to an individual in need thereof.

12. A method of treating bladder cancer, breast cancer, fallopian tube cancer, ovarian cancer, prostate cancer, peritoneal cancer, testicular cancer, endometrial cancer, or uterine cancer, comprising administering an effective amount of the pharmaceutical composition of claim 9 to an individual in need thereof.

13. The compound of claim 1 , wherein the compound is a compound of Formula IID or a pharmaceutically acceptable salt thereof.

14. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

15. The compound of claim 1 , wherein the compound is

16. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

17. The compound of claim 1 , wherein the compound is

18. The compound of claim 1 , wherein the compound is

or a pharmaceutically acceptable salt thereof.

19. The compound of claim 1 , wherein the compound is

Assignments (2)

Continuity (5)

References Cited (331)